Pharmacy evidence record · researched 2026-08-20

ReviveRX

Revive Rx LLC dba Revive Rx Pharmacy

7 citations2 action records4 explicit unknowns

Compounded with

Semaglutide

Not verified in the bound record.

Tirzepatide

FDA's 2025 warning letter documents the firm's distribution of compounded tirzepatide vials.

The first-party site currently presents a broad weight-management category but did not expose a public product catalog naming the drugs in the scrape.

Locations in the source record

  • 3831 Golf Drive, Suite A, Houston, TX 77018

Services named by sources

  • 503A patient-specific compounding
  • Mail-order pharmacy fulfillment
  • Custom formulations
  • Direct-to-patient delivery
  • Hormone, wellness, peptide, sexual-wellness, and weight-management categories

Regulatory compliance

503 pathway evidence

A pathway label describes which federal rules apply — it is not a quality claim.

Section 503A

Source-backed pathway evidence

ReviveRX identifies itself as a licensed 503A mail-order compounding pharmacy preparing patient-specific medications.

Section 503B

Not conclusively established

No exact Revive Rx match was found in the current FDA registered-outsourcing-facility check. This is not expanded into a categorical claim about every possible affiliate.

Telehealth providers

No provider relationship is verified in the bound sources.

Clinic Scout links a provider only when an explicit source names the relationship.

Browse provider records

Regulatory history

Actions stay dated and bounded.

FDA warning-letter, Form 483, compounding-action, current 503B-registry, and Texas license sources were checked. State-board action searches outside Texas were not exhaustively completed.

U.S. Food and Drug Administration · 2025-02-07

Form FDA 483

FDA issued inspection observations to Revive Rx LLC dba Revive Rx Pharmacy in Houston.

issued

U.S. Food and Drug Administration · 2025-09-22

Warning Letter

FDA stated that investigators observed serious deficiencies in sterile-drug production and documented distribution of tirzepatide 10 mg/mL 2 mL vials labeled as 4 mL. The warning letter also describes evaluation of corrective actions.

Status not stated

What remains unverified

No Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.

What this record verifies for you

6 evidence dimensions carry dated, source-backed verification.

Each line traces to a citation in the source list below — read the exact captured wording before relying on it.

No superiority claim is made for review volume, ratings, or patient sentiment.

Sources and exact captured wording

  1. first_party · accessed 2026-08-20
    ReviveRX is a nationwide compounding pharmacy built for healthcare providers. We prepare commercially available and custom-compounded medications in USP-compliant clean rooms and ship directly to your patients.
  2. first_party · accessed 2026-08-20
    ReviveRX is a licensed 503A mail-order compounding pharmacy ... Founded in 2016 with a clear vision to expand access to reliable compounded medications.
  3. first_party · accessed 2026-08-20
    shipping to 45 states ... Puerto Rico
  4. state_board · accessed 2026-08-20
    REVIVE RX, pharmacy license number 32011 ... Address: 3831 GOLF DR STE A, HOUSTON, TX 77018
  5. fda · accessed 2026-08-20
    During the inspection, FDA investigators documented that your firm distributed vials of Tirzepatide, 10mg/ml, 2ml, labeled as Tirzepatide, 10mg/ml, 4ml.
  6. fda · accessed 2026-08-20
    Revive Rx LLC dba Revive Rx Pharmacy Houston, TX 483 issued 02/07/2025
  7. fda · accessed 2026-08-20
    Updated as of 8/18/2026 ... This table lists the outsourcing facilities that have submitted registration information that has been determined to be complete by the data lock date for the latest weekly update of the table.

Questions readers ask

Is ReviveRX legit?

GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 7 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 4 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.

Still have questions? Read the research library or email us at [email protected].